

14th December, 2017

~~The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)~~

~~The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)~~

Dear Sir,

Sub: Torrent Pharmaceuticals Limited completes the acquisition of branded formulation business of Unichem Laboratories Limited


Torrent Pharmaceuticals Limited (“TPL”) has completed acquisition of branded formulation business of Unichem Laboratories Limited (“Unichem”) for India and Nepal, including its Sikkim manufacturing facility, on a going concern basis by way of slump sale, on 14th December, 2017. This transaction was in pursuance of the definitive binding agreement entered into between TPL and Unichem on 3rd November, 2017.

A Press release with respect to the above matter, which is being submitted to the media is enclosed herewith for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: A/a

Torrent Pharmaceuticals Limited completes the acquisition of branded formulation business of Unichem Laboratories Limited

Mumbai, 14th December, 2017: Torrent Pharmaceuticals Limited (“Torrent”) has completed acquisition of branded formulation business of Unichem Laboratories Limited (“Unichem”) for India and Nepal, including its Sikkim manufacturing facility, on a going concern basis by way of slump sale, on 14th December, 2017. This transaction was in pursuance of the definitive binding agreement entered into between Torrent and Unichem on 3rd November, 2017.

From today, Torrent begins the integration of the Unichem business following the successful closure of its acquisition. The integration will aim to fuel and support strong growth of the acquired Unichem brands, consolidating speciality reach with a relentless focus on enhancing productivity. The acquisition will accelerate Torrent's presence in the chronic space especially in the high growth segments of Indian Pharma market like Cardiology, Diabetology and Gastroenterology. Moreover, Unichem brings in an important new platform in Torrent's sustainable growth strategy by expanding the Company's presence in the OTC segment.

Torrent's. – India branded business enters the list of top pharma firms in the Indian Pharma market (IPM).

Commenting on the occasion, Mr. Samir Mehta, Chairman -Torrent Pharma said “The acquisition of Unichem's domestic branded business by Torrent Pharma is a major step forward in the Company's growth strategy in consolidating its India Business. Both companies Unichem and Torrent share a long and proud history in the Indian Pharma market with a common business culture, a factor which I believe will immensely aid in the successful integration of the combined business.”

About Torrent Pharmaceuticals Ltd.

Torrent Pharma, with annual revenues of more than INR 5,800 crores is the flagship Company of the INR 18,300 crore Torrent Group.

Torrent Pharma continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking amongst the top 50 brands (AIOCD AWACS Dataset) in India. Its widespread international presence also include several markets where Torrent is amongst the leading pharmaceutical companies in the respective countries.

Torrent has a fully equipped Research Centre, employing almost 900 scientists, to support the Company's operation and product pipeline for both Domestic and Overseas markets. The Company's manufacturing plants located at Indrad, Baddi, Sikkim, Dahej, Pithampur and Vizag have facilities to produce Formulation and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.

